Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Astrazeneca Plc ADR (NQ: AZN )

64.49 -0.20 (-0.31%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 8, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 10,352,067
Open 64.78
Bid (Size) 64.65 (1)
Ask (Size) 65.00 (2)
Prev. Close 64.69
Today's Range 64.27 - 65.04
52wk Range 60.47 - 87.67
Shares Outstanding N/A
Dividend Yield 1.44%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
AstraZeneca/Amgen's Asthma Drug Aces Late-Stage Study In Patients With Chronic Rhinosinusitis
AstraZeneca and Amgen's Phase 3 trial data shows Tezspire significantly reduces nasal polyps and congestion in patients with chronic rhinosinusitis with nasal polyps. 
Via Benzinga
TEZSPIRE met both co-primary endpoints in the Phase III WAYPOINT trial in patients with chronic rhinosinusitis with nasal polyps
From AstraZeneca
Via Business Wire

Performance

YTD
-5.72%
-5.72%
1 Month
-16.11%
-16.11%
3 Month
-21.85%
-21.85%
6 Month
-16.71%
-16.71%
1 Year
+2.09%
+2.09%

More News

Read More
AstraZeneca showcases strength of hematology portfolio and pipeline at ASH 2024
From AstraZeneca
Via Business Wire
Upstream Bio Is New On NASDAQ, Can Potentially Beat AstraZeneca's Asthma Drug On Efficacy, Analysts Say
Via Benzinga
Smart Money Is Betting Big In AZN Options
Via Benzinga
Why Is AstraZeneca Stock Sinking On Tuesday?
Via Benzinga
Volatility Hits Large Cap Biopharma: Active Rebalancing May Be Required
Via Talk Markets
AstraZeneca Unveils Early Data From Chinese-Firm Partnered Oral Weight Loss Drug
Via Benzinga
3 Magnificent Stocks Under $100 to Buy in November
Via The Motley Fool
3 Rock-Solid Dividend Stocks You Can Buy and Hold Forever
Via The Motley Fool
Monopar Therapeutics Skyrockets 400% on Licensing Deal
Via MarketBeat
Exposures COVID-19
Sanofi Earns $5B Q3 Core Profit On Strong Dupixent And Vaccine Sales, Raises 2024 Forecast
Via Benzinga
Monopar Therapeutics Stock Jumps 4X, Inks Licensing Pact With AstraZeneca For Once Terminated Phase 3 Candidate For Rare Genetic Disorder
Via Benzinga
Roche's Q3 Sales Surge Led By Ocrevus, Vabysmo, Urges Regulators To Block Novo Holdings' $16.5B Catalent Acquisition
Via Benzinga
Why Amgen's Obesity Drug — And $5 Billion Opportunity — Led To A Downgrade
Via Investor's Business Daily
GSK Settles Majority Of Zantac Lawsuits, But Pipeline Doubts Remain
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Biden Administration Unveils Plan To Provide Generic Drugs for $2 to Medicare Recipients
Via Benzinga
Want to Invest in the Weight Loss Boom? Consider Buying These 2 Stocks
Via The Motley Fool
Dow Tumbles Over 400 Points; Duckhorn Portfolio Shares Surge
Via Benzinga
Topics Stocks
Exposures US Equities
Crude Oil Gains Over 3%; Scholar Rock Shares Spike Higher
Via Benzinga
Exposures Fossil Fuels
US Stocks Open Lower; Dow Tumbles Over 150 Points
Via Benzinga
Topics Stocks
Exposures US Equities
AstraZeneca Inks $1.92B License Pact With Hong Kong-Based Firm To Boost Cardiovascular Pipeline
Via Benzinga
AIRSUPRA® (albuterol/budesonide) demonstrated statistically significant and clinically meaningful reduction in the risk of severe exacerbations in patients with intermittent or mild persistent asthma in BATURA Phase III trial
From AstraZeneca
Via Business Wire
Novo Nordisk/AstraZeneca's Manufacturing Partner Thermo Fisher Questioned Over Manufacturing Lapses
Via Benzinga
Exposures Product Safety
As Weight-Loss Drugs Battle, Upstart Viking Therapeutics Threatens Eli Lilly, Novo Nordisk, Pfizer
Via Investor's Business Daily
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.